Insulin Sensitivity during Combined Androgen Blockade for Prostate Cancer
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
CONTEXT: GnRH agonists markedly increase fat mass in men with prostate cancer, but little is known about the effects of treatment on insulin sensitivity. OBJECTIVE: The objective of the study was to assess the effects of short-term GnRH agonist treatment on insulin sensitivity. DESIGN: This was a prospective 12-wk study. SETTING: The study was conducted at a general clinical research center. PATIENTS OR OTHER PARTICIPANTS: We studied 25 men with locally advanced or recurrent prostate cancer, no radiographic evidence of metastases, no history of diabetes mellitus, and no evidence of diabetes mellitus at baseline visit. INTERVENTION: Leuprolide depot and bicalutamide were used in the study. MAIN OUTCOME MEASURES: Oral glucose tolerance tests and body composition assessment by dual-energy x-ray absorptiometry were performed at baseline and wk 12. The primary study outcome was change in insulin sensitivity index. RESULTS: Mean (+/- se) percentage fat body mass increased by 4.3 +/- 1.3% from baseline to wk 12 (P = 0.002). Insulin sensitivity index decreased by 12.9 +/- 7.6% (P = 0.02). Insulin sensitivity by homeostatic model assessment decreased by 12.8 +/- 5.9% (P = 0.02). Fasting plasma insulin levels increased by 25.9 +/- 9.3% (P = 0.04). Mean glycosylated hemoglobin also increased significantly (P < 0.001). CONCLUSIONS: Short-term treatment with leuprolide and bicalutamide significantly increased fat mass and decreased insulin sensitivity in men with prostate cancer. These observations suggest that GnRH agonists may increase the risk of diabetes mellitus and cardiovascular disease in older men.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Role of Insulin Resistance in Human Disease
Reaven, G. M. (1988) · Diabetes · doi:10.2337/diab.37.12.1595 · Cited by 12,154
Matsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621 · cited 4×
“The whole-body ISI was calculated from fasting plasma insulinandglucoseconcentrationsandmeanplasmainsulinandglucose concentrations during the OGTT, with ISI 10,000/square root of (fasting plasma glucose fasting plasma insulin) (mean OGTT glucose mean OGTT insulin) ( 18 ).”
BackgroundMethodResultInfluentialDeFronzo, R. A., & Ferrannini, E. (1991) · Diabetes Care · doi:10.2337/diacare.14.3.173 · Cited by 4,535 · cited 1×
“The observed increase in HDL cholesterol levels contrasts to the low levels of HDL cholesterol associated with the classic metabolic syndrome (14, 15 ).”
BackgroundPrevalence of Overweight and Obesity Among US Children, Adolescents, and Adults, 1999-2002
Hedley, A. A. (2004) · JAMA · doi:10.1001/jama.291.23.2847 · Cited by 4,460
Yudkin, J. S., Stehouwer, C. D. A., Emeis, J. J., & Coppack, S. W. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.4.972 · Cited by 2,465
Hyperinsulinemia as an independent risk factor for ischemic heart disease
Després, J.-P., Lamarche, B., Mauriège, P., Cantin, B., Dagenais, G. R., Moorjani, S., & Lupien, P.-J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199604113341504 · Cited by 1,699 · cited 1×
“Insulin resistance is a common metabolic abnormality that underlies type 2 diabetes mellitus (11) and is an independentriskfactorforcardiovasculardisease( 12 ,13).Insulin resistance is also linked to a variety of abnormalities associated with cardiovascular disease risk including obesity, hypertension, elevated trigly…”
BackgroundAndrogen Deprivation Therapy for Prostate Cancer
Sharifi, N. (2005) · JAMA · doi:10.1001/jama.294.2.238 · Cited by 1,083 · cited 1×
“nRH AGONISTS ARE the cornerstone of treatment for metastatic prostate cancer and a routine part of management for many men with local and local-regional disease ( 1 ).”
BackgroundFerrannini, E., Natali, A., Bell, P., Cavallo-Perin, P., Lalic, N., & Mingrone, G. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119628 · Cited by 898
Role of Insulin Resistance in Human Disease
Reaven, G. M. (1992) · Medical Science Symposia Series · doi:10.1007/978-94-011-2700-4_10 · Cited by 865
Changes in body composition during androgen deprivation therapy for prostate cancer
Smith, M. R., Finkelstein, J. S., McGovern, F. J., Zietman, A. L., Fallon, M. A., Schoenfeld, D. A., & Kantoff, P. W. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.2.8299 · Cited by 697 · cited 3×
“Consistent with earlier reports ( 5 , 8, 22), we observed that”
BackgroundMethodResultSelf-citation
Cited by
Items 201–300 of 496
New Players for Advanced Prostate Cancer and the Rationalisation of Insulin-Sensitising Medication
Gunter, J. H., Sarkar, P. L., Lubik, A. A., & Nelson, C. C. (2013) · International Journal of Cell Biology · doi:10.1155/2013/834684 · Cited by 31
“Metabolic dysfunction is a well-established side effect of ADT [34, 139].”
Metformin: On Ongoing Journey across Diabetes, Cancer Therapy and Prevention
Pulito, C., Sanli, T., Rana, P., Muti, P. C., Blandino, G., & Strano, S. (2013) · Metabolites · doi:10.3390/metabo3041051 · Cited by 33
“Moreover, this metformin effect could synergize with the common anti androgen therapies, which are usually prescribed for metastatic prostate cancer treatment [107].”
BackgroundMiller, C., Madden-Doyle, L., Jayasena, C., McIlroy, M., Sherlock, M., & O’Reilly, M. W. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae128 · Cited by 28
Androgen Deprivation Therapy for Prostate Cancer—Review of Indications in 2010
Quon, H. C., & Loblaw, D. A. (2010) · Current Oncology · doi:10.3747/co.v17i0.709 · Cited by 29
Outcomes of testosterone therapy in men with testosterone deficiency (TD): Part II
Traish, A. M. (2014) · Steroids · doi:10.1016/j.steroids.2014.05.004 · Cited by 29
Constantinou, C., Mpatsoulis, D., Νάτσος, Α., Πετροπούλου, Π.-Ι., Zvintzou, E., Traish, A. M., Voshol, P. J., Karagiannides, I., & Kypreos, K. E. (2014) · Journal of Lipid Research · doi:10.1194/jlr.m050047 · Cited by 29
Choi, S. L., & Lee, A. (2011) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s24106 · Cited by 27
Smith, M. R. (2008) · Current Urology Reports · doi:10.1007/s11934-008-0035-y · Cited by 30
Self-citationDiBlasio, C. J., Malcolm, J. B., Hammett, J., Wan, J. Y., Aleman, M. A., Patterson, A. L., Wake, R. W., & Derweesh, I. (2009) · British Journal of Urology · doi:10.1111/j.1464-410x.2009.08593.x · Cited by 28
Androgen-Deprivation Therapy in Prostate Cancer: A European Expert Panel Review
Schulman, C. C., Irani, J., Moróte, J., Schalken, J. A., Montorsi, F., Chłosta, P. L., & Heidenreich, A. (2010) · European Urology Supplements · doi:10.1016/j.eursup.2010.07.001 · Cited by 28
“Hormonal therapy reduces lean mass whilst increasing fat mass, raises serum cholesterol and triglycerides, decreases insulin sensitivity, and elevates fasting glucose and insulin [88–91].”
BackgroundSalvage therapy of small volume prostate cancer nodal failures: A review of the literature
Bari, B. D., Alongi, F., Buglione, M., Campostrini, F., Briganti, A., Berardi, G., Petralia, G., Bellomi, M., Chiti, A., Fodor, A., et al. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.11.003 · Cited by 27
Androgen-Deprivation Therapy and Metabolic Syndrome in Men With Prostate Cancer
Harrington, J. M., Schwenke, D. C., Epstein, D. R., & Bailey, D. E. (2013) · Oncology nursing forum · doi:10.1188/14.onf.21-29 · Cited by 26
“In addition, Smith, Lee, and Nathan (2006) used DEXA and oral glucose tolerance tests and found an increase in fat mass, fasting insulin, and mean glycosylated hemoglobin, as well as worsening insulin sensitivity in men receiving ADT after 12 weeks.”
InfluentialHuang, S., Bao, B., Hour, T., Huang, C., Yu, C., Liu, C., Lee, Y., Huang, C., Pao, J.-B., & Huang, C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041219 · Cited by 28
“While ADT controls the prostate cancer growth, it is also associated with a pattern of metabolic alterations, such as hyperinsulinaemia [38].”
BackgroundCardiac and Cognitive Effects of Androgen Deprivation Therapy: Are They Real?
Alibhai, S. M. H., & Mohamedali, H. Z. (2010) · Current Oncology · doi:10.3747/co.v17i0.698 · Cited by 27
Cardiovascular effect of testosterone replacement therapy in aging male.
Francomano, D., Bruzziches, R., Natali, M., Aversa, A., & Spera, G. (2010) · Acta bio-medica dell'Ateneo parmense/Acta biomedica · Cited by 29
Short-Term Estrogen Withdrawal Increases Adiposity in Healthy Men
Chao, J., Rubinow, K. B., Kratz, M., Amory, J. K., Matsumoto, A. M., & Page, S. T. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1482 · Cited by 25
Lateef, A., Khan, A. Q., Tahir, M., Khan, R., Rehman, M. U., Ali, F., Hamiza, O. O., & Sultana, S. (2012) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-012-1504-7 · Cited by 26
Abdollah, F., Sammon, J. D., Reznor, G., Sood, A. K., Schmid, M., Klett, D. E., Sun, M., Aizer, A. A., Choueiri, T. K., Hu, J. C., et al. (2015) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2015.06.011 · Cited by 26
Hoffman, K. E. (2012) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2012.05.005 · Cited by 32
Fradin, J. J., Kim, F. J., Lu-Yao, G. L., Storozynsky, E., & Kelly, W. K. (2023) · Cancers · doi:10.3390/cancers15082316 · Cited by 29
“, hyperlipidemia, elevated fasting blood glucose, hypertriglyceridemia, and increased weight) [13,14].”
BackgroundCardiovascular diseases and erectile dysfunction: the two faces of the coin of androgen deficiency
Yassin, A. A., Akhras, F., El‐Sakka, A. I., & Saad, F. (2010) · Andrologia · doi:10.1111/j.1439-0272.2009.01021.x · Cited by 25
Innovations in the systemic therapy of prostate cancer
Shepard, D. R., & Raghavan, D. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.187 · Cited by 24
The Interactions between Insulin and Androgens in Progression to Castrate-Resistant Prostate Cancer
Gunter, J. H., Lubik, A. A., McKenzie, I., Pollak, M., & Nelson, C. C. (2012) · Advances in Urology · doi:10.1155/2012/248607 · Cited by 28
“Related changes to the adipokine secretion profile of men receiving ADT may also contribute to reductions in insulin sensitivity [47, 71].”
BackgroundThe use of exercise interventions to overcome adverse effects of androgen deprivation therapy
Østergren, P. B., Kistorp, C., Bennedbæk, F. N., Faber, J. O., Sønksen, J., & Fode, M. M. (2016) · Nature Reviews Urology · doi:10.1038/nrurol.2016.67 · Cited by 24
Cardiovascular Complications of Androgen Deprivation Therapy for Prostate Cancer
Gupta, D., Salmane, C., Slovin, S. F., & Steingart, R. M. (2017) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-017-0563-1 · Cited by 26
“A small short-term prospective study of nondiabetic men with prostate cancer on GnRH agonists showed significantly decreased insulin sensitivity and increased fasting plasma insulin and glycosylated hemoglobin levels at week 12 compared with baseline [24].”
BackgroundScailteux, L., Naudet, F., Alimi, Q., Vincendeau, S., & Oger, E. (2016) · Medicine · doi:10.1097/md.0000000000003873 · Cited by 26
Bayram, F., Elbüken, G., Korkmaz, C., Aydoğdu, A., Karaca, Z., & Çakır, I. (2015) · Hormone and Metabolic Research · doi:10.1055/s-0035-1564252 · Cited by 23
Kokorovic, A., So, A., Serag, H. A., French, C., Hamilton, R. J., Izard, J., Nayak, J. G., Pouliot, F., Saad, F., Shayegan, B., et al. (2021) · Canadian Urological Association Journal · doi:10.5489/cuaj.7355 · Cited by 26
“Metabolic changes The metabolic consequences of ADT include insulin resistance, glucose intolerance and changes to lipid profile (49) (50).”
BackgroundSafety and tolerability of intermittent androgen deprivation therapy: A literature review
Gruca, D., Bacher, P. H., & Tunn, U. W. (2012) · International Journal of Urology · doi:10.1111/j.1442-2042.2012.03001.x · Cited by 24
Teoh, J. Y., Chiu, P. K., Chan, S. Y. S., Poon, D. M. C., Cheung, H., Hou, S. S. M., & Ng, C. (2015) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyv025 · Cited by 23
“Firstly, ADT reduces insulin sensitivity within a short period of time (32), which does not necessarily confer a greater cumulative risk with time.”
BackgroundAversa, A., Bruzziches, R., Francomano, D., Natali, M., & Lenzi, A. (2009) · Therapeutic Advances in Urology · doi:10.1177/1756287209344992 · Cited by 24
“Pilot studies suggest that T may have a role as an antiatherogenic therapy, by preserving endothelial and smooth-muscle cell integrity; also, recent evidence demonstrated that androgen deprivation for prostate cancer may reduce insulin sensitivity, thus suggesting a key role for T in the development of insulin resista…”
BackgroundCollins, L. F., & Basaria, S. S. (2012) · Asian Journal of Andrology · doi:10.1038/aja.2011.109 · Cited by 26
Newton, R. U., Taaffe, D. R., Spry, N. A., Cormie, P., Chambers, S. K., Gardiner, R. A., Shum, D., Joseph, D. J., & Galvao, D. A. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-432 · Cited by 25
“However, ADT leads to a range of wellestablished musculoskeletal toxicities including reduced bone mass and increased skeletal fractures[7,8] compounded with rapid metabolic alterations including increased body fat, loss of lean mass, insulin resistance and negative lipoprotein profile[9-15].”
BackgroundAndrogen deprivation therapy promotes an obesity-like microenvironment in periprostatic fat
Mangiola, S., Stuchbery, R., McCoy, P. J., Chow, K., Kurganovs, N. J., Kerger, M., Papenfuss, A. T., Hovens, C. M., & Corcoran, N. M. (2019) · Endocrine Connections · doi:10.1530/ec-19-0029 · Cited by 26
“For example, gonadotropin-releasing hormone agonists have been shown to alter tissue lipid profiles with cholesterol levels, triglycerides and high-density lipoproteins shown to increase up to 10.6, 25 and 8–20%, respectively (8, 10).”
InfluentialGilbert, S. E., Tew, G. A., Bourke, L., Winter, E., & Rosario, D. J. (2013) · Experimental Physiology · doi:10.1113/expphysiol.2013.073353 · Cited by 25
“Although body fat accumulation and increased insulin resistance have been demonstrated in the first 3 months after initiation of ADT (Smith et al. 2006), hyperglycaemia has been reported only in patients treated with ADT for a minimum of 12 months (Basaria et al. 2006; Mohamedali et al. 2011),…”
BackgroundInfluentialA Holistic Approach to Androgen Deprivation Therapy: Treating the Cancer without Hurting the Patient
TOMBAL, B. F. (2009) · Urologia Internationalis · doi:10.1159/000251174 · Cited by 22
Metabolic Syndrome as a Peculiar Target for Management of Prostate Cancer Patients
Conteduca, V., Lorenzo, G. D., Bozza, G., Ardito, R., & Aieta, M. (2013) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2013.04.009 · Cited by 22
“Studies have showed that even short-term (12 weeks) use of ADT significantly increased fat mass and decreased insulin sensitivity in men with prostate cancer.(3) Another important aspect of the association between metabolic syndrome and prostate cancer is the increased cardiovascular morbidity and mortality in patient…”
BackgroundŽiaran, S., Gonçalves, F., & Breza, J., Jr. (2012) · World Journal of Urology · doi:10.1007/s00345-012-0926-x · Cited by 22
“strated that ADT decreases insulin sensitivity [15, 16] alters cholesterol levels and lipoprotein profile [17] and causes unfavorable changes in body composition [18], all”
BackgroundObesity and the Odds of Weight Gain following Androgen Deprivation Therapy for Prostate Cancer
Braunstein, L. Z., Chen, M., Loffredo, M. J., Kantoff, P. W., & D'Amico, A. V. (2014) · Prostate Cancer · doi:10.1155/2014/230812 · Cited by 22
Donner, D. G., Elliott, G. E., Beck, B. R., Bulmer, A. C., & Toit, E. F. D. (2015) · PLoS ONE · doi:10.1371/journal.pone.0138019 · Cited by 25
Androgen Deprivation Therapy for Prostate Cancer
Pagliarulo, V. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-99286-0_1 · Cited by 28
Androgen deprivation therapy through bilateral orchiectomy: increased metabolic risks
Bo, J., Zhang, C., Zhang, L., Liu, P., Sha, J., Lv, J., Liu, D., Huang, Y., & Li, Z. (2011) · Asian Journal of Andrology · doi:10.1038/aja.2011.83 · Cited by 22
Men’s Health in Primary Care: An Emerging Paradigm of Sexual Function and Cardiometabolic Risk
Miner, M. M. (2011) · Urologic Clinics of North America · doi:10.1016/j.ucl.2011.09.003 · Cited by 23
Maximal Exercise Testing of Men with Prostate Cancer Being Treated with Androgen Deprivation Therapy
Wall, B. A., Galvao, D. A., Fatehee, N. N., Taaffe, D. R., Spry, N. A., Joseph, D. J., & Newton, R. U. (2014) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000000353 · Cited by 24
“Several studies have reported negative metabolic changes after short-term (3 months) ADT (12,34,36), suggesting that an acute exposure”
BackgroundMetabolic Syndrome in Prostate Cancer: Impact on Risk and Outcomes
Karzai, F. H., Madan, R. A., & Dahut, W. L. (2016) · Future Oncology · doi:10.2217/fon-2016-0061 · Cited by 24
Breen, K. J., O’Neill, A., Murphy, L., Fan, Y., Boyce, S., Fitzgerald, N. M., Dorris, E., Brady, L., Finn, S. P., Hayes, B. D., et al. (2017) · The Prostate · doi:10.1002/pros.23389 · Cited by 21
“Hormonal therapy is known to alter mens metabolic profile leading to hyperinsulinemia.(43,44) In a radical prostatectomy cohort (n = 287), Keto et al(45) found that obese men treated with early androgen”
BackgroundComplex Metabolic and Skeletal Changes in Men Taking Long-Term Androgen Deprivation Therapy
Žiaran, S., Gonçalves, F., & Sn, J. B. (2012) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2012.08.005 · Cited by 20
Cheung, A. S., Tinson, A. J., Milevski, S. V., Hoermann, R., Zajac, J. D., & Grossmann, M. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0117 · Cited by 21
Metabolic syndrome in castration-resistant prostate cancer patients treated with abiraterone
Conteduca, V., Caffo, O., Derosa, L., Veccia, A., Petracci, E., Chiurì, V. E., Santoni, M., Santini, D., Fratino, L., Maines, F., et al. (2015) · The Prostate · doi:10.1002/pros.23014 · Cited by 20
“Other recent study have showed that even short-term use of ADT (4–6 months) significantly increases fat mass and decreases insulin sensitivity in PC men [18].”
BackgroundTestosterone and cardiovascular disease – the controversy and the facts
Morgentaler, A., Feibus, A. H., & Baum, N. H. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2015.996111 · Cited by 22
“Many of these men experience changes in body composition such as a decrease in lean muscle mass and an increase in fat mass [29].”
BackgroundPerpetuating effects of androgen deficiency on insulin resistance
Cameron, J. L., Jain, R., Rais, M., White, A. E., Beer, T. M., Kievit, P., Winters‐Stone, K. M., Messaoudi, I., & Varlamov, O. (2016) · International Journal of Obesity · doi:10.1038/ijo.2016.148 · Cited by 19
Smith, M. R., O’Malley, A. J., & Keating, N. L. (2008) · British Journal of Urology · doi:10.1111/j.1464-410x.2008.07707.x · Cited by 20
Self-citationBourke, L., Chico, T., Albertsen, P. C., Hamdy, F. C., & Rosario, D. J. (2011) · Heart · doi:10.1136/heartjnl-2011-300893 · Cited by 22
Radiotherapy combined with hormonal therapy in prostate cancer: the state of the art
Milecki, P. (2010) · Cancer Management and Research · doi:10.2147/cmar.s8912 · Cited by 18
Parekh, A., Chen, M., Graham, P. L., Mahal, B. A. V., Hirsch, A. E., Nakabayashi, M., Evan, C. P., Kantoff, P. W., Martin, N. E., & Nguyen, P. L. (2014) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2014.06.016 · Cited by 18
Prostate Cancer and Osteoporosis
Tuck, S. P., Hanusch, B. C., Walker, J., & Datta, H. K. (2013) · Current Osteoporosis Reports · doi:10.1007/s11914-012-0131-2 · Cited by 21
Intervening on the Side Effects of Hormone-Dependent Cancer Treatment: The Role of Strength Training
Hanson, E. D., & Hurley, B. F. (2011) · Journal of Aging Research · doi:10.4061/2011/903291 · Cited by 20
“in insulin sensitivity were found after a 12-week prospective study at the onset of ADT [32].”
BackgroundEndobiogeny: A Global Approach to Systems Biology (Part 2 of 2)
Lapraz, J.-C., Hedayat, K. M., & Pauly, P. (2013) · Global Advances in Health and Medicine · doi:10.7453/gahmj.2013.013 · Cited by 21
Higano, C. S. (2020) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2020.07.004 · Cited by 18
Cleffi, S., Neto, A. S., Reis, L. O., Maia, P., Fonseca, F., Wroclawski, M. L., Neves, M., Pompeo, A. C. L., del Giglio, A., Faria, E. F., et al. (2011) · Actas Urológicas Españolas (English Edition) · doi:10.1016/j.acuroe.2011.06.007 · Cited by 18
Impact of Acute Biochemical Castration on Insulin Sensitivity in Healthy Adult Men
Rabiee, A., Dwyer, A. A., Caronia, L. M., Hayes, F. J., Yialamas, M. A., Andersen, D. K., Thomas, B. J., Torriani, M., & Elahi, D. (2010) · Endocrine Research · doi:10.3109/07435801003705601 · Cited by 19
“The importance of T’s effects on body composition is illustrated by the reduction in FFM seen in both young (44) and older men (22,45) in whom hypogonadism is induced with a GnRH agonist.”
BackgroundCardiovascular risk during androgen deprivation therapy for prostate cancer
Jones, T. H. (2011) · BMJ · doi:10.1136/bmj.d3105 · Cited by 18
Physical Activity and Genitourinary Cancer Survivorship
Galvao, D. A., Taaffe, D. R., Spry, N. A., & Newton, R. U. (2010) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-04231-7_9 · Cited by 17
“Several studies have documented marked alterations in body composition in men receiving ADT for prostate cancer ( Smith et al. 2001, 2002, 2006, 2008; Smith 2004; Greenspan et al. 2005; Lee et al. 2005; Galvao et al. 2008) (Table 9.2).”
BackgroundInfluentialThe role of the urologist in the prevention and early detection of cardiovascular disease
Yassin, A. A., Saad, F., Haider, A., & Gooren, L. J. (2011) · Arab Journal of Urology · doi:10.1016/j.aju.2011.03.014 · Cited by 18
“Studies in men undergoing androgen deprivation treatment in prostate cancer show that within 3 months significant metabolic changes have occurred (a 43% increase in fat mass and a 26% increase in insulin levels) [31].”
BackgroundHolmes, J. A., Anderson, R. F., Hoffman, L. G., Showalter, T. N., Kasibhatla, M. S., Collins, S. P., Papagikos, M. A., Barbosa, B. D., Alligood, K., Stravers, L., et al. (2018) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2018.07.2018 · Cited by 17
Short term testosterone replacement therapy improves libido and body composition
Júnior, E. S. D. A., Clapauch, R., & Buksman, S. (2009) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302009000800014 · Cited by 17
Lloyd, J. C., Antonelli, J. A., Phillips, T. E., Masko, E. M., Thomas, J.-A., Poulton, S. H. M., Pollak, M., & Freedland, S. J. (2010) · The Journal of Urology · doi:10.1016/j.juro.2009.12.003 · Cited by 15
Moustsen‐Helms, I. R., Larsen, S. B., Duun‐Henriksen, A. K., Tjønneland, A. M., Kjær, S. K., Brasso, K., Johansen, C., & Dalton, S. O. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0468-8 · Cited by 15
Androgen Deprivation Therapy in High-Risk Localized and Locally Advanced Prostate Cancer
Iwamoto, H., Izumi, K., Makino, T., & Mizokami, A. (2022) · Cancers · doi:10.3390/cancers14071803 · Cited by 18
The role of gonadotropin releasing hormone in normal and pathologic endocrine processes
Rothman, M. S., & Wierman, M. E. (2007) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3281e2c9fc · Cited by 15
Cleffi, S., Neto, A. S., Reis, L. O., Maia, P., Fonseca, F., Wroclawski, M. L., Neves, M., Pompeo, A. C. L., del Giglio, A., Faria, E. F., et al. (2011) · Actas Urológicas Españolas · doi:10.1016/j.acuro.2011.01.011 · Cited by 17
“9% with a small increase of HbA1c.(17) In a cross-sectional study comparing 16 men undergoing ADT for ≥1 year, 14 age-matched eugonadal men with localized prostate cancer who had local therapy, and 14 age-controlled eugonadal men with no previous history of Documento descargado de http://www.”
BackgroundInfluentialEffect of Androgen Deprivation Therapy on Metabolic Complications and Cardiovascular Risk
Melloni, C., & Nelson, A. J. (2019) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-019-09942-w · Cited by 15
Moryousef, J., Duivenvoorden, W., Leong, D. P., & Pinthus, J. H. (2024) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-024-00897-x · Cited by 16
“[40, 41] A second possible mechanism relates to the role of the immune system as T cells have been shown to express GnRH receptors which may potentially promote atherosclerotic plaque destabilization and expansion through GnRH receptor activation.”
Current and Future Management of Locally Advanced and Metastatic Prostate Cancer.
Shore, N. D. (2020) · PubMed · Cited by 21
Androgen deprivation therapy for prostate cancer: implications for cardiometabolic clinical care.
Collins, L. F., Mohammed, N., Ahmad, T. A., & Basaria, S. S. (2012) · PubMed · doi:10.3275/8284 · Cited by 16
Foulkes, S., Daly, R. M., & Fraser, S. F. (2017) · Endocrine Related Cancer · doi:10.1530/erc-16-0505 · Cited by 14
Davey, P. P., & Alexandrou, K. (2022) · International Journal of Clinical Practice · doi:10.1155/2022/2976811 · Cited by 17
“For example, treatment with GnRH agonists can lead to diabetes (due to the development of insulin resistance or altered insulin sensitivity), obesity, and other metabolic changes, including changes in lipid levels, which can exacerbate atherosclerotic diseases [44, 51–55].”
Saylor, P. J., Keating, N. L., Freedland, S. J., & Smith, M. R. (2011) · Drugs · doi:10.2165/11588930-000000000-00000 · Cited by 16
“Significant changes in serum lipid profile can be observed within 3 months of initiation of therapy.([24,25]) Finally, GnRH agonists decrease insulin sensitivity.”
BackgroundInfluentialSelf-citationChen, K., Chen, C.-R., Chen, C.-Y., Tzou, K.-Y., Peng, C.-C., & Peng, R. Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093400 · Cited by 14
“Administration of leuprolide and bicalutamide significantly decreased insulin sensitivity, implying the potential of androgen-deprivation therapy (ADT) to elicit DM [20].”
BackgroundEnergy balance in cancer survivors at risk of weight gain: a review
McNeil, J. (2022) · European Journal of Nutrition · doi:10.1007/s00394-022-02975-z · Cited by 16
An overview of hormonal directed pharmacotherapy for the treatment of prostate cancer
Mitsogianni, M., Papatsoris, A., Bala, V.-M., Issa, H., Moussa, M. J., & Mitsogiannis, I. C. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2244415 · Cited by 13
“…of diabetes mellitus was shown, in a meta-analysis, to be increased in patients on ADT (RR 1.39, 95% CI 1.27–1.53, p < 0.001) [33]; also, leuprolide and bicalutamide have been found to significantly decrease insulin sensitivity and increase fat mass in patients with prostate cancer [33,34].”
BackgroundInfluentialTestosterone, obesity, diabetes and the metabolic syndrome
Jones, T. H., & Channer, K. S. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9781139003353.012 · Cited by 13
Androgens and Coronary Artery Disease
Wu, F. C. W., & von Eckardstein, A. (2003) · Humana Press eBooks · doi:10.1385/1-59259-388-7:191 · Cited by 13
Goserelin acetate in combination with radiotherapy for prostate cancer
Roach, M., & Izaguirre, A. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.2.257 · Cited by 13
“Recent studies have demonstrated that in men with prostate cancer, common complications resulting from the use of LHRH agents are osteoporosis-associated risk of fractures, increased abdominal obesity, fat mass and decreased insulin sensitivity [32-36].”
BackgroundDiabetes and Cancer: Epidemiological, Clinical, and Experimental Perspectives
Tseng, C., Chen, C., & Landolph, J. R. (2012) · Experimental Diabetes Research · doi:10.1155/2012/101802 · Cited by 14
Wong, C. H. M., Xu, N., Lim, J., Feng, K.-K., Chan, W. K., Chan, M. T. Y., Leung, S. C. H., Chen, D., Lin, Y., Chiu, P. K., et al. (2023) · The Prostate · doi:10.1002/pros.24519 · Cited by 12
“Previous literatures have demonstrated significant increase in cholesterol levels within as early as 3 or 6 months of ADT initiation.(20,22,24,29) The change in lipid profiles seems to be more short‐lived, with our data set demonstrating a peaked increase of total cholesterol at 6 months and triglycerides at 12 months.”
BackgroundResultLipid Status During Combined Treatment in Prostate Cancer Patients
Wolny-Rokicka, E. I., Tukiendorf, A., Wydmański, J., Ostrowska, M., & Zembroń-Łacny, A. (2019) · American Journal of Men s Health · doi:10.1177/1557988319876488 · Cited by 12
Miraj, S., Forood, A. K., Azimi, S., Panahinia, P., Ebadi, E., Moradpanah, S., Nayebzadeh, M., & Etezadi, A. (2025) · Cardiovascular Toxicology · doi:10.1007/s12012-025-10025-3 · Cited by 12
“Mechanistically, GnRH agonists and antagonists appear to influence insulin sensitivity by disrupting the normal hormonal balance that regulates glucose homeostasis [107, 108].”
Shastri, B. R., & Yaturu, S. (2011) · Prostate Cancer · doi:10.1155/2011/391576 · Cited by 14
“[28] 12 weeks NR NS Higher with ADT∗ NS: Not significant; NR: Not reported; ∗P < 0.”
BackgroundInfluentialKokorovic, A., So, A., Serag, H. A., French, C., Hamilton, R. J., Izard, J., Nayak, J. G., Pouliot, F., Saad, F., Shayegan, B., et al. (2022) · Canadian Urological Association Journal · doi:10.5489/cuaj.8054 · Cited by 12
Advances in the management of high‐risk localised and metastatic prostate cancer
Bellmunt, J., Attard, G., Bahl, A. K., Huland, H., Klotz, L. H., Kuban, D. A., Oudard, S. M., & Watson, R. W. G. (2012) · British Journal of Urology · doi:10.1111/j.1464-410x.2011.10871.x · Cited by 12
Schmid, M., Hanske, J., Ravi, P. K., Krishna, N., Reznor, G., Meyer, C. P., Fisch, M., Noldus, J., Nguyen, P. L., & Trinh, Q. (2016) · International Journal of Urology · doi:10.1111/iju.13043 · Cited by 12
Gagliano‐Jucá, T., Burak, M. F., Pencina, K. M., Li, Z., Edwards, R. R., Travison, T. G., & Basaria, S. S. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01068 · Cited by 12
Cardiovascular Complications of Prostate Cancer Therapy
Campbell, C. M., Zhang, K. W., Collier, A., Linch, M. D., Calaway, A. C., Ponsky, L. E., Guha, A., & Ghosh, A. K. (2020) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-020-00873-3 · Cited by 12
Domingo, J. J. S., Alonso‐Gordoa, T., Álvaro, J. L., Molina‐Cerrillo, J., Barquín, A., Martínez‐Sáez, O., Revilla, J. B., Carrato, A., & Rodríguez, S. Á. (2021) · Therapeutic Advances in Urology · doi:10.1177/17562872211043341 · Cited by 13
Adiponectin and testosterone in patients with symptoms of late‐onset hypogonadism: Is there a link?
Tsujimura, A., Takada, S., Matsuoka, Y., Nakayama, J., Takao, T., Miyagawa, Y., Sonoda, M., Nishizawa, H., Iwahashi, H., Funahashi, T., et al. (2009) · International Journal of Urology · doi:10.1111/j.1442-2042.2009.02376.x · Cited by 11
Prostate Carcinogenesis with Diabetes and Androgen-Deprivation-Therapy-Related Diabetes: An Update
Hara, N. (2012) · Experimental Diabetes Research · doi:10.1155/2012/801610 · Cited by 12
“Insulin resistance appears early during ADT; some previous prospective studies showed that increased fasting insulin levels already emerge in 26–63% of the patients 3 months after the inception of ADT [51, 52].”
ResultEtezadi, A., Marashi, S. M., Nazari, L., Sina, M., Nasab, F. S., Amirlatifi, S., Zamanifard, S., Zahiri, Z., & Khodaparast, F. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118860 · Cited by 10
Assessing the effects of prostate cancer therapies on cardiovascular health
Tisseverasinghe, S., Tolba, M., Bahoric, B., Saad, F., & Niazi, T. M. (2025) · Nature Reviews Urology · doi:10.1038/s41585-025-01002-0 · Cited by 10
“showed increased subcutaneous fat, insulin resistance, fasting glucose levels and sarcopenia, as well as worsening glycosylated haemoglobin levels in these patients 30,31 .”
Don’t think once, think twice! the cardiovascular effects of androgen deprivation therapy
Jefferies, E., Thurairaja, R., Persad, R. A., Rajani, R., Phull, J., & Bahl, A. K. (2011) · British Journal of Urology · doi:10.1111/j.1464-410x.2011.10097.x · Cited by 10
Metadata
- Authors
- Smith, M. R., Lee, H., & Nathan, D. M.
- Affiliations
- Massachusetts General Hospital (US)
- Corresponding author
- Smith, Matthew R.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2006-04
- Volume
- 91
- Issue
- 4
- Pages
- 1305-1308
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2129509910
- Cited by
- 493
- References
- 25
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 14 · 2023: 12 · 2022: 13 · 2021: 9 · 2020: 14 · 2019: 15 · 2018: 20 · 2017: 25 · 2016: 24 · 2015: 26 · 2014: 26 · 2013: 35 · 2012: 46
- FWCI
- 32.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Prostate Cancer Foundation
- Massachusetts General Hospital
- National Institutes of Health
- National Cancer Institute (P50 CA 90381, P50CA090381)
- National Center for Research Resources (M01RR001066, M01-RR01066)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Keywords
- insulin sensitivity, prostate cancer, combined androgen blockade, GnRH agonist, leuprolide, bicalutamide, fat mass, insulin resistance, diabetes risk, cardiovascular risk, fasting insulin, HbA1c
- MeSH terms
- Adipose Tissue, Adult, Androgen Antagonists, Anthropometry, Blood Glucose, Body Composition, Glucose Tolerance Test, Glycated Hemoglobin, Humans, Insulin, Insulin Resistance, Gonadotropin-Releasing Hormone, Lipids, Male, Prospective Studies, Prostatic Neoplasms, Testosterone, Biomarkers, Absorptiometry, Photon, Treatment Outcome, Antineoplastic Agents, Hormonal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.